Or, if you're already a Process Excellence member, sign in below to view this content. Sign In Join
For years pharmaceutical companies could rake in high margins on drugs that were protected by patents. But as many patents have expired or are near expiration – so much so that the industry is calling it the "patent cliff" – pharma companies are having to look much harder at how they can streamline processes in R&D to save time and money.
In this Process Perspectives podcast, Andrew Parson, VP Preclinical Drug Development at GlaxoSmithKline and Gerald Fincken, CEO of CSM Clinical trials, discuss some of the changes they’ve seen in the industry and how process excellence needs to play a more pivotal role.